HCV Protease

HCV NS3-4A serine protease is a non-covalent heterodimer consisting of a catalytic subunit (the N-terminal one-third of NS3 protein) and an activating cofactor (NS4A protein), and is responsible for cleavage at four sites of the HCV polyprotein. HCV NS3-4A protease is essential for viral replication in cell culture and in chimpanzees, and has been considered as one of the most attractive targets for developing novel anti-HCV therapies. However, discovery of small-molecule, selective inhibitors against HCV NS3-4A protease as oral drug candidates has been hampered by its shallow substrate-binding groove and the lack of robust, reproducible viral replication models in cell culture or in small animals.

HCV Protease Inhibitors & Antagonists

ACH-806
(GS9132) Cat. No.: HY-19512

ACH-806 is an **NS4A** antagonist which can inhibit Hepatitis C Virus (**HCV**) replication with an **EC_{50}** of 14 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Asunaprevir
(BMS-650032) Cat. No.: HY-14434

Asunaprevir is a potent **hepatitis C virus (HCV) NS3 protease** inhibitor, with **IC_{50}** of 0.2 nM-3.5 nM.



Purity: 99.27%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

Beclabuvir
(BMS-791325) Cat. No.: HY-12429

Beclabuvir is an allosteric inhibitor that binds to thumb site 1 of the hepatitis C virus (**HCV**) NS5B RNA-dependent RNA polymerase, and inhibits recombinant NS5B proteins from HCV genotypes 1, 3, 4, and 5 with **IC_{50}** of < 28 nM. .



Purity: 99.81%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Boceprevir
(EBP 520; SCH 503034) Cat. No.: HY-10237

Boceprevir is a novel, potent, highly selective, orally bioavailable **HCV NS3 protease** inhibitor with **K_i** of 14 nM in both enzyme assay and **EC_{90}** of 350 nM in cell-based replicon assay.



Purity: 99.12%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Clemizole
Cat. No.: HY-30234

Clemizole is an **H1 histamine receptor** antagonist, is found to substantially inhibit **HCV** replication. The **IC_{50}** of Clemizole for RNA binding by **NS4B** is 24±1 nM, whereas its **EC_{50}** for viral replication is 8 μM.



Purity: >98%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg

Clemizole hydrochloride
Cat. No.: HY-30234A

Clemizole hydrochloride is an **H1 histamine receptor** antagonist, is found to substantially inhibit **HCV** replication. The **IC_{50}** of Clemizole for RNA binding by **NS4B** is 24±1 nM, whereas its **EC_{50}** for viral replication is 8 μM.



Purity: 99.32%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Daclatasvir
(BMS-790052; EBP 883) Cat. No.: HY-10466

Daclatasvir is a potent **HCV NS5A** protein inhibitor, with mean **EC_{50}** values of 50 and 9 pM against genotype 1a and 1b replicons, respectively.



Purity: 99.31%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Daclatasvir dihydrochloride
(BMS-790052 dihydrochloride) Cat. No.: HY-10465

Daclatasvir dihydrochloride (BMS-790052 dihydrochloride) is a highly selective inhibitor of HCV NS5A with EC50 of 9-50 pM, for a broad range of HCV replicon genotypes and the JFH-1 genotype 2a infectious virus in cell culture.



Purity: 99.70%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Danoprevir
(ITMN-191; R7227; RO5190591; RG7227) Cat. No.: HY-10238

Danoprevir (ITMN-191) is an orally active **NS3/4A protease** inhibitor for hepatitis C virus (HCV) with an **IC_{50}** of 0.29 nM and is selective for NS3/4A over a panel of 53 proteases (**IC_{50}** higher than 10 μM).



Purity: 97.13%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

Elbasvir
(MK-8742) Cat. No.: HY-15789

Elbasvir (MK-8742) is a hepatitis C virus nonstructural protein 5A (**HCV NS5A**) inhibitor with **EC_{50}**s of 4, 3 and 3 nM against genotype 1a, 1b, and 2a, respectively.



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

Filibuvir

Cat. No.: HY-10118

Filibuvir is a potent, selective non-nucleoside inhibitor (NNI) of the **HCV nonstructural 5B protein (NS5B) RNA-dependent RNA polymerase**, and it binds noncovalently in the "Thumb 2" pocket of NS5B.



Purity: 98.09%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Glecaprevir

(ABT-493)

Cat. No.: HY-17634

Glecaprevir is a novel **HCV NS3/4A protease** inhibitor, with IC_{50} values ranging from 3.5 to 11.3 nM.



Purity: 99.65%
Clinical Data: Launched
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg

Grazoprevir

(MK-5172)

Cat. No.: HY-15298

Grazoprevir (MK-5172) is a selective inhibitor of **Hepatitis C virus NS3/4a** protease with broad activity across genotypes and resistant variants, with K_is of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively.



Purity: 99.21%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Grazoprevir hydrate

(MK-5172 (hydrate))

Cat. No.: HY-15298B

Grazoprevir hydrate (MK-5172 hydrate) is a selective inhibitor of **Hepatitis C virus NS3/4a** protease with broad activity across genotypes and resistant variants, with K_is of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively.



Purity: 99.58%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Grazoprevir potassium salt

(MK-5172 (potassium salt))

Cat. No.: HY-15298A

Grazoprevir potassium salt (MK-5172 potassium salt) is a selective inhibitor of **Hepatitis C virus NS3/4a** protease with broad activity across genotypes and resistant variants, with K_is of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively.



Purity: 99.35%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Grazoprevir sodium salt

(MK-5172 (sodium salt))

Cat. No.: HY-15298C

Grazoprevir sodium salt (MK-5172 sodium salt) is a selective inhibitor of **Hepatitis C virus NS3/4a** protease with broad activity across genotypes and resistant variants, with K_is of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively.



Purity: >98%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg, 100 mg

HCV-IN-4

Cat. No.: HY-P0162

HCV-IN-4 is a potent and orally active **HCV NS5A** inhibitor, shows great potency against GT1a, GT2b, GT3a, GT1a Y93H and GT1a L31V, with EC_{90}s of 3 pM, 0.3 nM, 0.01 nM, 0.5 nM and 0.02 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 300 mg

Ledipasvir

(GS-5885)

Cat. No.: HY-15602

Ledipasvir is an inhibitor of the **hepatitis C virus NS5A**, with EC_{50}s of 34 pM and 4 pM against genotype 1a and 1b replicon, respectively.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ledipasvir acetone

(GS-5885 acetone)

Cat. No.: HY-15602A

Ledipasvir acetone is the active pharmaceutical ingredient of Ledipasvir. Ledipasvir is an inhibitor of the **hepatitis C virus NS5A**, with EC_{50} values of 34 pM against GT1a and 4 pM against GT1b replicon.



Purity: 99.95%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ledipasvir D-tartrate

(GS-5885 D-tartrate)

Cat. No.: HY-15602B

Ledipasvir D-tartrate is an inhibitor of the **hepatitis C virus NS5A**, with EC_{50} values of 34 pM against GT1a and 4 pM against GT1b replicon.



Purity: 99.73%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ledipasvir diacetone

(GS-5885 diacetone) Cat. No.: HY-15602D

Ledipasvir diacetone is the active pharmaceutical ingredient of Ledipasvir. Ledipasvir is an inhibitor of the **hepatitis C virus NS5A**, with EC_{50} values of 34 pM against GT1a and 4 pM against GT1b replicon.



Purity: >98%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg, 100 mg

Mericitabine

(RG 7128; R-7128; PSI 6130 diisobutyrate) Cat. No.: HY-10240

Mericitabine (R-7128) is a nucleoside inhibitor of the **HCV NS5B polymerase** that acts as an RNA chain terminator and prevents elongation of RNA transcripts during replication.



Purity: 99.34%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Narlaprevir

(SCH 900518) Cat. No.: HY-10300

Narlaprevir is a potent, selective, orally bioavailable NS3 protease inhibitor(Ki=6 nM; EC90=40 nM).



Purity: 97.51%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Ombitasvir

(ABT-267) Cat. No.: HY-13997

Ombitasvir is a potent inhibitor of the **hepatitis C virus protein NS5A**, with EC_{50}s of 0.82 to 19.3 pM against HCV genotypes 1 to 5, and 366 pM against genotype 6a.



Purity: 99.79%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PSI-6130

(R 1656) Cat. No.: HY-10165

PSI-6130 is a potent and selective inhibitor of **HCV NS5B polymerase**, and inhibits HCV replication with a mean IC_{50} of 0.6 μM. .



Purity: 99.39%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

Simeprevir

(TMC435) Cat. No.: HY-10241

Simeprevir (TMC435) is an oral and potent **HCV NS3/4A protease** inhibitor with a K_i of 0.36 nM, and inhibits HCV replication with an EC_{50} of 7.8 nM.



Purity: 99.34%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Telaprevir

(VX-950) Cat. No.: HY-10235

Telaprevir is a highly selective, reversible, and potent peptidomimetic inhibitor of the **HCV NS3-4A protease**, the steady-state inhibitory constant (K_i) of Telaprevir is 7 nM against a genotype 1 (H strain) NS3 protease domain plus a NS4A cofactor peptide.



Purity: 99.89%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

TMC647055 Choline salt

Cat. No.: HY-15591A

TMC647055 choline salt is a cell-permeating, selective HCV NS5B inhibitor, eliciting a mean IC50 of 34 nM, as assessed in the RdRp primer-dependent transcription assay.



Purity: 99.75%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Vaniprevir

(MK-7009) Cat. No.: HY-10243

Vaniprevir (MK-7009) is a non-covalent competitive inhibitor of the hepatitis C virus (HCV) NS3/4A protease.



Purity: 99.60%
Clinical Data: Launched
Size: 5 mg, 10 mg

VCH-916

Cat. No.: HY-13465

VCH-916 is a novel nonnucleoside HCV NS5B polymerase inhibitor.



Purity: 99.51%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Velpatasvir

(GS-5816) **Cat. No.:** HY-12530

Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons.



Purity: 99.95%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Voxilaprevir

(GS-9857) **Cat. No.:** HY-19840

Voxilaprevir (GS-9857) is a fluorinated macrocyclic **hepatitis C virus (HCV) nonstructural protein (NS) 3/4A protease** inhibitor with potent in vitro antiviral activity against genotypes 1-6 HCV and broad coverage of NS3/4A protease polymorphisms.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

VX-222

(VCH-222) **Cat. No.:** HY-75800

VX-222 (VCH-222) is a novel, potent and selective inhibitor of HCV polymerase with IC50 of 0.94-1.2 μM, 15.3-fold less effective for mutant M423T, and 108-fold less effective for mutant I482L.



Purity: 99.76%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg